enGene
Christine Tosone, MS, RAC has extensive experience in the biotechnology and pharmaceutical industry. Their most recent role is as the VP, Head of Clinical Development Operations at enGene, a biotechnology company specializing in non-viral gene therapy. Prior to joining enGene, Christine served as the Executive Director of Clinical Development Operations at Allena Pharmaceuticals, Inc. and as the Vice President of Clinical at Neurotech USA, Inc. Christine also held senior positions at AMAG Pharmaceuticals, AVANT Immunotherapeutics, and Circe Biomedical. Christine has a strong background in clinical operations and regulatory affairs.
Christine Tosone holds a Bachelor of Science (BS) degree in Biology from Stonehill College. Christine also has a Master of Science (MS) degree in Clinical Cardiovascular and Exercise Physiology from Northeastern University. In 2000, they obtained the Regulatory Affairs Certification from RAPS.
This person is not in any offices
enGene
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications